Which equity should we work through?
Thirteen roles read the filings, argue both sides, and record a verdict with the dissents kept beside it — impersonal, and identical for every reader.
Not investment advice. Impersonal research, published to every reader alike, and not tailored to your circumstances.
Revenue is up 20.4% year on year with gross margin at 40.1% and 174M of net cash, and the stock holds above both moving averages. The bear's concentration and valuation points keep conviction at medium and the position sized down.
Halvane Grid Storage has a strong order book but margins are compressing as cell costs rise, so the price already reflects the growth and offers no fresh entry.
Brixmere Retail's same-store sales have declined for three quarters while inventory keeps building, and the balance sheet leaves little room if discounting continues.
Zelquor Therapeutics' outlook hinges on a single trial readout and the sample filings do not support a directional view either way, so the run abstains.
Request a run on your own ticker
Pick a ticker. Running the panel on it needs a free account.
- Analysts
- Debate
- Trader
- Risk
- Verdict